Taking stock of the drug industry, from the lab to the medicine chestNovember 18, 2025Check out STAT+Sponsored By By Ed SilvermanPharmalot Columnist, Senior Writer Nardus Engelbrecht/AP STAT+ | Trump administration touts moves to provide HIV prevention drug, but refuses to include South Africa An official would not explain why lenacapavir would not be provided to South Africa under the effort, which started in Eswatini and Zambia. By Ed Silverman STAT+ | Novo Nordisk's $199 Ozempic deal shows what telehealth platforms can do for pharma Novo Nordisk and telehealth companies are teaming up to route patients to cash-pay GLP-1 drugs, reshaping marketing and access in weight loss care. By Katie Palmer Opinion: Could an HIV miracle drug actually reach people like my parents? A medical student who grew up in Zimbabwe, Tatenda Makoni writes that bringing lencapavir to those who need it most is harder than it may sound. By Tatenda Makoni Nam Y. Huh/AP STAT+ | Trump and RFK Jr. are mulling their most disruptive vaccine policies yet — alarming manufacturers Trump and Kennedy push to reformulate vaccines into single shot doses, remove aluminum leaves drugmakers warning of shortages and risks for kids. By Daniel Payne STAT+ | FDA's stronger warning on Sarepta gene therapy raises new questions about heart risk Risk of "acute, serious, and life-threatening" heart inflammation is now on the label of Sarepta's gene therapy for Duchenne muscular dystrophy. By Adam Feuerstein and Jason Mast More around STATCheck out more exclusive coverage with a STAT+ subscriptionRead premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.Enjoying Pharmalot? Tell us about your experienceContinue reading the latest health & science news with the STAT appDownload on the App Store or get it on Google Play STAT, 1 Exchange Place, Boston, MA©2025, All Rights Reserved.I no longer wish to receive STAT emailsUpdate Newsletter Preferences • Contact Us • Advertise with Us • View in Browser
No comments